• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载体诱导的表位抑制通过克隆优势启动。

Carrier-induced epitopic suppression is initiated through clonal dominance.

作者信息

Schutze M P, Deriaud E, Przewlocki G, LeClerc C

机构信息

Laboratoire de Biologie des Régulations Immunitaires, Institut Pasteur, Paris, France.

出版信息

J Immunol. 1989 Apr 15;142(8):2635-40.

PMID:2467933
Abstract

Injection of mice with an immunogenic dose of carrier followed by immunization with hapten-carrier conjugate selectively suppresses anti-hapten antibody response. Previous studies have proposed that this epitopic suppression is related to the induction of carrier-specific Ts cells which in turn could inhibit selectively anti-hapten response. In the present study, we propose that the epitopic suppression is in fact due to clonal dominance. Immunization with a carrier such as tetanus toxoid induces a clonal expansion of carrier-specific B cells, thus decreasing the probability of hapten-specific B cells to react with the Ag. Increasing the density of the TNP-hapten on the conjugate has totally prevented the induction of the epitopic suppression. Moreover, using low hapten-carrier concentrations to challenge carrier-primed mice has enhanced the induction of the suppression. Finally, priming hapten-specific B cells before carrier/hapten-carrier immunization has also abrogated the suppression. The results of these experiments support the view that epitopic suppression is induced through the expansion of the clones specific for the carrier epitopes and resulted from intra-molecular antigenic competition between hapten and carrier epitopes. Based on these findings a regulatory role is proposed for B cells, where through their capacity to process and present antigen, they would exercise a strong influence on the selection of immune responses.

摘要

给小鼠注射免疫原剂量的载体,随后用半抗原-载体偶联物进行免疫,可选择性地抑制抗半抗原抗体反应。先前的研究提出,这种表位抑制与载体特异性 Ts 细胞的诱导有关,而这些 Ts 细胞反过来又可选择性地抑制抗半抗原反应。在本研究中,我们提出表位抑制实际上是由于克隆优势。用诸如破伤风类毒素之类的载体进行免疫可诱导载体特异性 B 细胞的克隆扩增,从而降低半抗原特异性 B 细胞与抗原反应的概率。增加偶联物上 TNP-半抗原的密度可完全阻止表位抑制的诱导。此外,使用低浓度的半抗原-载体来攻击预先用载体致敏的小鼠可增强抑制作用的诱导。最后,在载体/半抗原-载体免疫之前对半抗原特异性 B 细胞进行致敏也可消除抑制作用。这些实验结果支持这样一种观点,即表位抑制是通过载体表位特异性克隆的扩增诱导产生的,并且是由半抗原和载体表位之间的分子内抗原竞争导致的。基于这些发现,提出了 B 细胞的一种调节作用,即通过其处理和呈递抗原的能力,它们会对免疫反应的选择产生强烈影响。

相似文献

1
Carrier-induced epitopic suppression is initiated through clonal dominance.载体诱导的表位抑制通过克隆优势启动。
J Immunol. 1989 Apr 15;142(8):2635-40.
2
The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression.体内清除CD4+ T细胞可阻止载体诱导的表位抑制的诱导,但不能阻止其表达。
J Immunol. 1990 Sep 1;145(5):1343-9.
3
Carrier-induced, hapten-specific suppression: a problem of antigen presentation?
J Immunol. 1998 Jul 15;161(2):702-6.
4
Bypass of carrier-induced epitope-specific suppression using a T-helper epitope.利用辅助性T细胞表位绕过载体诱导的表位特异性抑制作用
Immunology. 1992 Aug;76(4):599-603.
5
Carrier-induced suppression of the antibody response to a 'self' hapten.载体诱导的对“自身”半抗原抗体应答的抑制
Immunology. 1991 Oct;74(2):223-7.
6
Alloantigen pretreatment induces a down-regulation of the in vivo subsequent development of cytotoxic T lymphocytes directed against linked alloantigens.
Eur J Immunol. 1989 Aug;19(8):1365-71. doi: 10.1002/eji.1830190803.
7
Ocular immune responses. II. Priming of A/J mice in the vitreous induces either enhancement of or suppression of subsequent hapten-specific DTH responses.眼部免疫反应。II. 在玻璃体中对A/J小鼠进行致敏可诱导随后的半抗原特异性迟发型超敏反应增强或抑制。
J Immunol. 1986 Apr 15;136(8):2787-91.
8
Suppression of reaginic antibody formation. III. Relationship between immunogenecity and tolerogenicity of hapten-carrier conjugates.反应素性抗体形成的抑制。III. 半抗原-载体结合物的免疫原性与耐受性之间的关系。
J Immunol. 1976 Jun;116(6):1711-8.
9
Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms.合成疫苗模型中的表位抑制:效应机制分析
Cell Immunol. 1987 Jan;104(1):79-90. doi: 10.1016/0008-8749(87)90008-6.
10
T cells specific to hapten carrier but not to carrier alone assist in the production of anti-hapten and anti-carrier antibodies.对半抗原载体特异而非仅对载体特异的T细胞,协助产生抗半抗原和抗载体抗体。
Int Immunol. 2007 Oct;19(10):1157-64. doi: 10.1093/intimm/dxm080. Epub 2007 Sep 19.

引用本文的文献

1
Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.野生型和突变型乙型肝炎表面抗原病毒样颗粒(VLPs)在对野生型载体具有预先存在免疫的小鼠中的免疫原性。
Viruses. 2023 Jan 23;15(2):313. doi: 10.3390/v15020313.
2
Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.用 NA1 和 NA2 神经氨酸酶病毒样颗粒进行二价疫苗接种可预防 H1N1 和 H3N2 甲型流感病毒在小鼠模型中的挑战。
Virology. 2021 Oct;562:197-208. doi: 10.1016/j.virol.2021.08.001. Epub 2021 Aug 5.
3
Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice.
破伤风类毒素的既有免疫力对破伤风类毒素结合海洛因疫苗在小鼠中疗效的影响。
Vaccines (Basel). 2021 Jun 1;9(6):573. doi: 10.3390/vaccines9060573.
4
Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.抗原结构和组成设计以提高基于蛋白质的疫苗效力。
Front Immunol. 2020 Feb 24;11:283. doi: 10.3389/fimmu.2020.00283. eCollection 2020.
5
Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses.通过共价脂质体连接与表面排列的 B 细胞靶抗原共递呈 CD4 T 细胞辅助表位可促进更高亲和力的抗体反应。
Vaccine. 2018 Oct 1;36(41):6191-6201. doi: 10.1016/j.vaccine.2018.08.014. Epub 2018 Sep 7.
6
Factors contributing to the immunogenicity of meningococcal conjugate vaccines.导致脑膜炎球菌结合疫苗免疫原性的因素。
Hum Vaccin Immunother. 2016 Jul 2;12(7):1808-24. doi: 10.1080/21645515.2016.1153206. Epub 2016 Mar 2.
7
Hib Vaccines: Past, Present, and Future Perspectives.Hib 疫苗:过去、现在和未来的展望。
J Immunol Res. 2016;2016:7203587. doi: 10.1155/2016/7203587. Epub 2016 Jan 20.
8
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.结合疫苗的蛋白载体:特性、研发和临床试验。
Hum Vaccin Immunother. 2013 Dec;9(12):2505-23. doi: 10.4161/hv.26109. Epub 2013 Aug 16.
9
A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.一种新型四聚体 gp350 1-470 作为潜在的 Epstein-Barr 病毒疫苗。
Vaccine. 2013 Jun 26;31(30):3039-45. doi: 10.1016/j.vaccine.2013.04.071. Epub 2013 May 9.
10
Combination vaccines.联合疫苗
J Glob Infect Dis. 2011 Jan;3(1):63-72. doi: 10.4103/0974-777X.77298.